Xu, Jingjuan
Wang, Ruirui
You, Shengfu
Zhang, Lei
Zheng, Peiyong
Ji, Guang
Liu, Baocheng
Funding for this research was provided by:
three-year action plan for Shanghai (ZY(2018-2020)-CCCX-2001-01)
the shanghai hospital development center (16CR4024A)
National Natural Science Foundation of China (81620108030)
National Natural Science Foundation of China (81603411, 81573814)
China Postdoctoral Science Foundation (2018M630465)
Article History
Received: 6 January 2019
Accepted: 5 May 2020
First Online: 10 June 2020
Ethics approval and consent to participate
: The study protocol was approved by the Medical ethics committee of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (ref. approval no. 2017LCSY069) and we will not begin recruiting until obtaining local ethical approval. Before the implementation of the study, the study protocol was modified three times and approved by the ethics committee, respectively. The final protocol version was V3.0. We will guarantee that this study is conducted in the principles of the Declaration of Helsinki and the principles of the Quality Control of Clinical Trial of Drugs in China. All participants need to sign the informed consent before enrollment, and will be informed about the purpose, probable risks and benefits, arrangement, the rights and obligations, and can quit the study at any time. Signed informed consent from patient willing to participate in the trial will be collected by clinical investigators. The informed consent form will be available from the corresponding author on request.
: Not applicable.
: The authors declare no competing interests.